603 results on '"Vender, Ronald"'
Search Results
2. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
3. A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
4. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
5. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
6. A systematic review of recent randomized controlled trials for palmoplantar pustulosis.
7. Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
8. Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
9. Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
10. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
11. Mobilizing an institutional supportive response for healthcare workers and other staff in the context of COVID-19: The Yale experience
12. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
13. Management of Guttate Psoriasis: A Systematic Review.
14. Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council
15. From treatment to trigger: a systematic review of imiquimod‐induced psoriasis
16. Clinical mimickers of cutaneous melanoma in skin of colour: a systematic review of cases.
17. Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.
18. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
19. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
20. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
21. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
22. Evaluation of Vision LLMs GTP-4V and LLaVA for the Recognition of Features Characteristic of Melanoma
23. Research productivity among Canadian first year dermatology residents: A 15 year analysis
24. Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study
25. Clinical Goals and Barriers to Effective Psoriasis Care
26. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
27. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
28. Association Between Parkinson’s Disease and Psoriasis: A Scoping Review
29. PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials
30. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
31. Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review
32. Mechanism of Action of Acitretin
33. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
34. Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
35. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
36. Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital Visits
37. Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis who recently failed guselkumab: a multicentre retrospective study of switching within the interleukin-23 inhibitor class
38. Management of adult generalized pustular psoriasis using biologics: A systematic review
39. Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
40. Supplementary material - Supplemental material for Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis
41. Plaque psoriasis and morphea in a patient on ustekinumab: A case report
42. Adalimumab-induced systemic lupus erythematosus: A case report and review of the literature
43. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway
44. Under-Reporting of COVID-19 Infections in Psoriasis Patients on Biologics
45. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
46. Pharmacology of TNF inhibitors
47. Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
48. Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
49. 33108 Ixekizumab achieved and sustained nail psoriasis resolution regardless of disease severity through 5 years: Results from Uncover-3
50. 53750 Improvements in Patient-Reported Symptoms and Signs of Moderate-to-Severe Psoriasis With JNJ-77242113: Results of the FRONTIER 1 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.